Key Insights

Highlights

No notable highlights available yet

Clinical Risk Assessment

Based on trial outcomes

High Risk

Score: 85/100

Termination Rate

20.0%

1 terminated out of 5 trials

Success Rate

0.0%

-86.5% vs benchmark

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed with results

Key Signals

0

Data Visualizations

Phase Distribution

5Total
Not Applicable (1)
P 1 (2)
P 2 (2)

Trial Status

Recruiting2
Terminated1
Unknown1
Withdrawn1

Clinical Trials (5)

Showing 5 of 5 trials
NCT06027086Phase 1RecruitingPrimary

DRP-104 (Glutamine Antagonist) in Combination With Durvalumab in Patients With Advanced Stage Fibrolamellar Carcinoma (FLC)

NCT05937295Phase 1RecruitingPrimary

FusionVAC22_01: Fusion Transcript-based Peptide Vaccine Combined with Immune Checkpoint Inhibition

NCT05681949Not ApplicableUnknown

Therapeutic Assistance and Decision-making Algorithms in Hepatobiliary Tumor Boards

NCT02702960Phase 2WithdrawnPrimary

Sequential, Related Donor Partial Liver Transplantation Followed by Bone Marrow Transplantation for Hepatocellular Carcinoma (HCC)

NCT01215565Phase 2Terminated

Study of Sunitinib in Patients With Advanced/Inoperable Fibrolamellar Carcinoma

Showing all 5 trials

Research Network

Activity Timeline